Skip to content

Fructo-oligosaccharides and Irritable Bowel Syndrome

Effect of Dietary Supplementation With Fructo-oligosaccharides on Visceral Sensitivity and on Taxonomic and Functional Composition of Intestinal Microbiota of IBS Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00806104
Enrollment
60
Registered
2008-12-10
Start date
2009-03-31
Completion date
2010-12-31
Last updated
2011-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome

Brief summary

Fructo-oligosaccharides are known as prebiotic ingredients to modulate the composition of the intestinal microbiota and particularly to stimulate the growth of Bifidobacteria. Imbalance of the intestinal microbiota such as reduction of Bifidobacteria is implicated in Irritable Bowel Syndrome (IBS). Thus the objective of the study is to evaluate the effect of fructo-oligosaccharides to improve IBS score and to explore which modifications of the microbiota are responsible of this improvement.

Interventions

DIETARY_SUPPLEMENTFructo-oligosaccharides

Dietary supplementation for 4 weeks

DIETARY_SUPPLEMENTMaltodextrins

Dietary supplementation for 4 weeks

Sponsors

Beghin-Meiji
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* IBS subjects according to Rome III criteria * Incomfort below or equivalent to 30mmHg during Tensostat test * between 18 and 60 years * no antibiotic treatment for the last 2 months * less than 20g of dietary fibres consummed per day * no analgesic treatment * no treatment for intestinal transit

Exclusion criteria

* subjects suffering from diabetes, colic cancer, inflammatory bowel disease, dysthyroidy, Hirschprung disease, anorexia * excessive consumption of alcohol or tobacco * participating to another clinical study * pregnant women * antidepressor or anxiolytic treatment

Design outcomes

Primary

MeasureTime frame
rectal sensitivity4 weeks

Secondary

MeasureTime frame
taxonomic composition of intestinal microbiota4 weeks

Countries

France, Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026